- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06335173
Un estudio para evaluar la eficacia y seguridad del ACU193 intravenoso en participantes con enfermedad de Alzheimer temprana (ALTITUDE-AD) (ALTITUDE-AD)
Un ensayo de diseño adaptativo de fase 2/3, doble ciego, aleatorizado y controladora con placebo para evaluar la eficacia y seguridad del ACU193 intravenoso en la enfermedad de Alzheimer temprana
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania
- Charité - Universitaetsmedizin Berlin
-
Cologne, Alemania
- University Hospital of Cologne
-
Mannheim, Alemania
- Zentralinstitut für seelische Gesundheit
-
Munich, Alemania
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Canadá
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa, Ontario, Canadá
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto, Ontario, Canadá
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park, Quebec, Canadá
- MoCA Research and Innovations
-
-
-
-
-
Barcelona, España
- Fundacio ACE
-
Donostia / San Sebastian, España
- Policlínica Gipuzkoa
-
Getxo, España
- Cae Oroitu
-
Madrid, España
- Hospital Ruber
-
Seville, España
- Hospital Victoria Eugenia
-
Valencia, España
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès, Barcelona, España
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva, Zaragoza, España
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
California
-
Carlsbad, California, Estados Unidos, 92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton, California, Estados Unidos, 92835
- Neurology Center of North Orange County
-
Irvine, California, Estados Unidos, 92614
- Irvine Medical Research
-
Long Beach, California, Estados Unidos, 90804
- Healthy Brain Research
-
Santa Ana, California, Estados Unidos, 92705
- Syrentis Clinical Research
-
Sherman Oaks, California, Estados Unidos, 91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk, Connecticut, Estados Unidos, 06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis, Florida, Estados Unidos, 33462
- JEM Research Institute
-
Bradenton, Florida, Estados Unidos, 34205
- Bradenton Research Center
-
Coral Gables, Florida, Estados Unidos, 33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach, Florida, Estados Unidos, 33445
- Brain Matters Research
-
Homestead, Florida, Estados Unidos, 33032
- Coral Clinical Research
-
Lady Lake, Florida, Estados Unidos, 32159
- K2 Medical Research - Villages
-
Miami, Florida, Estados Unidos, 33126
- Finlay Medical Research
-
Naples, Florida, Estados Unidos, 34105-8522
- Aqualane Clinical Research
-
Ocala, Florida, Estados Unidos, 34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange, Florida, Estados Unidos, 32127
- Progressive Medical Research
-
Stuart, Florida, Estados Unidos, 34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa, Florida, Estados Unidos, 33607
- K2 Medical Research - Tampa
-
The Villages, Florida, Estados Unidos, 32162
- Charter Research - Lady Lake
-
Wellington, Florida, Estados Unidos, 33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park, Florida, Estados Unidos, 32789
- Conquest Research
-
Winter Park, Florida, Estados Unidos, 32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31909
- Columbus Memory Center
-
Decatur, Georgia, Estados Unidos, 30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook, Illinois, Estados Unidos, 60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton, Massachusetts, Estados Unidos, 02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth, New Hampshire, Estados Unidos, 03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield, New Jersey, Estados Unidos, 07081
- The Cognitive and Research Center of New Jersey
-
Toms River, New Jersey, Estados Unidos, 08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews, North Carolina, Estados Unidos, 28105
- AMC Research
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97210
- Summit Research Network
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Abington Neurological Associates
-
Norristown, Pennsylvania, Estados Unidos, 19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova, Tennessee, Estados Unidos, 38018
- Neurology Clinic. P.C
-
Knoxville, Tennessee, Estados Unidos, 37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin, Texas, Estados Unidos, 78757
- Senior Adult Specialty Research
-
Beaumont, Texas, Estados Unidos, 77702
- Gadolin Research, LLC
-
Dallas, Texas, Estados Unidos, 75231
- Kerwin Medical Center
-
-
-
-
-
Bristol, Reino Unido
- Re:Cognition Health - Bristol
-
-
Greater London
-
London, Greater London, Reino Unido
- Re:Cognition Health - London
-
London, Greater London, Reino Unido
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester, Hampshire, Reino Unido
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell, Lanarkshire, Reino Unido
- Neuroclin Glasgow
-
-
Lancashire
-
Preston, Lancashire, Reino Unido
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford, Surrey, Reino Unido
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield, Yorkshire, Reino Unido
- Panthera Biopartners - Sheffield
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
Experimental: DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
Comparador de placebos: DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
Experimental: Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
Periodo de tiempo: Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de participantes con eventos adversos relacionados con el tratamiento (TEAE)
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Número de participantes con eventos adversos graves (EAG) y eventos adversos de interés especial (AESI)
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Número de participantes que interrumpen o se retiran debido a TEAE
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Número de participantes con anticuerpos antidrogas (ADA) y anticuerpos neutralizantes
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Número de participantes con anomalías en las imágenes relacionadas con amiloide con edema/derrames (ARIA-E) y ARIA con hemorragia/deposición de hemosiderina (ARIA-H), medida mediante imágenes por resonancia magnética (MRI)
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Concentraciones de ACU193 en el LCR en un subconjunto de participantes
Periodo de tiempo: Hasta la semana 76
|
Hasta la semana 76
|
|
|
Cambio desde el valor inicial en la carga o depósito de placa amiloide medida mediante tomografía por emisión de positrones (PET) en centiloides
Periodo de tiempo: Línea de base hasta la semana 76
|
Línea de base hasta la semana 76
|
|
|
Cambio con respecto al valor inicial en las imágenes de resonancia magnética volumétrica (vMRI) del volumen total del cerebro, el volumen ventricular y el volumen de regiones de interés seleccionadas
Periodo de tiempo: Línea de base hasta la semana 76
|
Línea de base hasta la semana 76
|
|
|
Cambio con respecto al valor inicial en las concentraciones de amiloide, tau y otros biomarcadores neurodegenerativos en el LCR
Periodo de tiempo: Línea de base hasta la semana 76
|
Línea de base hasta la semana 76
|
|
|
Cambio con respecto al valor inicial en las concentraciones de amiloide, tau y otros biomarcadores neurodegenerativos en el LCR en un subconjunto de participantes
Periodo de tiempo: Línea de base hasta la semana 76
|
Línea de base hasta la semana 76
|
|
|
Cambio con respecto al valor inicial en las concentraciones sanguíneas de amiloide, tau y otros biomarcadores neurodegenerativos
Periodo de tiempo: Línea de base hasta la semana 76
|
Línea de base hasta la semana 76
|
|
|
Efecto de sabirnetug sobre la progresión clínica en comparación con el placebo evaluado mediante un análisis de ahorro de tiempo medido por iADRS
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Efecto de sabirnetug sobre la progresión clínica en comparación con el placebo evaluado mediante un análisis de ahorro de tiempo medido por ADCS-iADL
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Efecto de sabirnetug sobre la progresión clínica en comparación con el placebo evaluado mediante un análisis de ahorro de tiempo medido por ADAS-Cog13
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Efecto de sabirnetug sobre la progresión clínica en comparación con el placebo evaluado mediante un análisis de ahorro de tiempo medido por CDR-SB
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Efecto de sabirnetug sobre la progresión clínica en comparación con el placebo evaluado mediante un análisis de ahorro de tiempo medido por MMSE
Periodo de tiempo: Línea de base hasta la semana 80
|
Línea de base hasta la semana 80
|
|
|
Concentración sérica de sabirnetug
Periodo de tiempo: Predosis y múltiples momentos posteriores a la dosis hasta 80 semanas
|
Predosis y múltiples momentos posteriores a la dosis hasta 80 semanas
|
|
|
Concentración de sabirnetug en líquido cefalorraquídeo (LCR)
Periodo de tiempo: Hasta la semana 76
|
Hasta la semana 76
|
|
|
Compromiso objetivo evaluado mediante la medición del complejo sabirnetug-oligómero β-amiloide (AβO) en el LCR
Periodo de tiempo: Hasta la semana 76
|
Hasta la semana 76
|
|
|
Change from Baseline in ADCS-iADL Score
Periodo de tiempo: Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
Periodo de tiempo: Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Periodo de tiempo: Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
Periodo de tiempo: Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
Periodo de tiempo: Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
Periodo de tiempo: Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
Periodo de tiempo: Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
Periodo de tiempo: Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
Periodo de tiempo: Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
Periodo de tiempo: Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Periodo de tiempo: Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
Periodo de tiempo: Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
Periodo de tiempo: Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Trastornos cognitivos
- Demencia
- Tauopatías
- Enfermedades neurodegenerativas
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Disfunción congnitiva
- Enfermedad de Alzheimer
- Trastornos de la memoria
Otros números de identificación del estudio
- ACU193-201
- 2023-509807-34-00 (Identificador de registro: EU CT Number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .